Dyslipidaemia Clinical Trial
Official title:
CEntralized Pan-Russian Survey of tHE Undertreatment of hypercholeSterolemia II
This is a multi-center survey of patients who are currently receiving lipid-lowering medications and have a moderate or higher cardiovascular (CV) risk. The survey will be conducted in the Russian Federation. Data collection for each study subject will be done within one physician visit. If an enrolled subject comes to the visit not fasting (for at least 8 hours), an appointment for the blood tests will be made for another day.
This is a multi-center survey of patients who are currently receiving lipid-lowering
medications and have a moderate or higher CV risk. The survey will be conducted in the
Russian Federation.
Data collection for each study subject will be done within one physician visit. If an
enrolled subject comes to the visit not fasting (for at least 8 hours), an appointment for
the blood tests will be made for another day.
Prior to the assessment of the first subject at a site, each investigator will complete an
investigator questionnaire on his/her experience and perception of the management of
hypercholesterolemia in his/her patients.
Prior to the assessment, subjects will record on a patient questionnaire their awareness of
hypercholesterolemia, their current treatment schedule, their perception, and compliance.
The investigator will complete a Case Report Form (CRF) with the subject's demographics,
known cardiovascular risk factors, cardiovascular medical history, current lipid-lowering
drug therapy, and the reason for this therapy.
Fasting blood samples will be taken in tubes to test for total cholesterol, low-density
lipoprotein cholesterol (LDL), high-density lipoprotein cholesterol (HDL), glucose,
creatinine, hemoglobin A1c, hemoglobin, and hematocrit at a central laboratory in the
Russian Federation.
;
Observational Model: Cohort, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04641299 -
A Study of AZD8233 in Participants With Dyslipidemia
|
Phase 2 | |
| Completed |
NCT01451918 -
Regulation of Intestinal and Hepatic Lipoprotein Secretion by Resveratrol
|
Phase 2 | |
| Recruiting |
NCT01212328 -
A Multi-site, Individually Randomized, Controlled Translation Trial of Integrated and Comprehensive Care Strategies to Reduce Cardiovascular Disease (CVD) Risk Among 1,120 Type 2 Diabetes Mellitus(T2DM) Patients in South Asia
|
N/A | |
| Completed |
NCT01221584 -
Centralized Pan-Russian Survey on the Undertreatment of Hypercholesterolemia
|
N/A | |
| Completed |
NCT00654225 -
Treatment of Hypercholesterolaemia in South Asian Subjects (IRIS)
|
Phase 3 | |
| Withdrawn |
NCT02557412 -
Effect of Nasal CPAP on Lipid Profile in Patients With Dyslipidaemia and Sleep Apnea
|
N/A | |
| Completed |
NCT00653965 -
Treatment of Hypercholesterolaemia in Hispanic Subjects (STARSHIP)
|
Phase 3 | |
| Recruiting |
NCT04442334 -
The European NAFLD Registry
|
||
| Completed |
NCT00653744 -
Rosuvastatin Versus Atorvastatin in the Treatment of Hypercholesterolaemia in African American Subjects(ARIES)
|
Phase 3 | |
| Completed |
NCT01632358 -
Safety and Pharmacokinetis of TAP311 in Dyslipidemic Patients
|
Phase 1 | |
| Completed |
NCT02523391 -
Bioequivalence Study of Capsule and Tablet Formulations of TA-8995
|
Phase 1 | |
| Completed |
NCT00474864 -
Study To Evaluate The Effects Of GW856553 On Endothelial Function/Vascular Compliance In Subjects With Dyslipidaemia.
|
Phase 2 | |
| Completed |
NCT00659321 -
Efficacy of Nicotine Acid on Dyslipidaemia in Patients With Metabolic Syndrome
|
Phase 3 | |
| Completed |
NCT01055977 -
Statin Therapy Results in the Real World Practice in the Czech Republic
|
N/A | |
| Completed |
NCT00654602 -
48-wk Open Label Phase IIIb to Evaluate Efficacy and Safety
|
Phase 3 | |
| Recruiting |
NCT05979428 -
A Study to Look at How Safe a New Medicine (NNC0491-6075) is in Healthy People and in Participants With High Levels of Fat in the Blood
|
Phase 1 | |
| Completed |
NCT02241759 -
Study of the Electrocardiographic Effects of TA-8995
|
Phase 1 | |
| Completed |
NCT00158899 -
GW501516 In Subjects Who Have Low Level Of High-Density Lipoprotein Cholesterol
|
Phase 2 |